{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:35:54Z","timestamp":1789785354261,"version":"4.0.1"},"reference-count":4,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,26]]},"abstract":"Abstract<\/jats:title>\n \n Objectives<\/jats:title>\n This study aimed to assess differences in insulin-like growth factor 1 (IGF-1) levels following the transition from somatropin to lonapegsomatropin in patients with pediatric growth hormone deficiency (GHD). Secondary objectives included the evaluation of dose titrations based on IGF-1 levels, changes in annualized height velocity (AHV) and body mass index (BMI), and assessing reported adverse effects associated with lonapegsomatropin therapy.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A single-center, retrospective review was conducted including patients diagnosed with pediatric GHD initially treated with somatropin who transitioned to lonapegsomatropin between January 1, 2022, and December 31, 2023.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Fourteen patients (median age: 9 years) were included. The median somatropin dose was 0.18\u202fmg\/kg\/week (range, 0.09 to 0.29) at the time of transition and patients were initiated on a median lonapegsomatropin dose of 0.23\u202fmg\/kg\/week (range, 0.15 to 0.26). This resulted in an IGF-1 increase of 2.3 SDS post-switch. Dose adjustments were made based on IGF-1 levels. Five patients required immediate dose reductions; four of these required further adjustments due to persistent elevation. There were no serious adverse effects reported.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Lonapegsomatropin may be a favorable option to reduce injection burden for those with pediatric GHD, though the manufacturer\u2019s recommended starting dose of 0.24\u202fmg\/kg\/week may require individualization. Careful monitoring and dose adjustment based on IGF-1 levels are necessary to maintain safety and efficacy.<\/jats:p>\n <\/jats:sec>","DOI":"10.1515\/jpem-2024-0496","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T03:20:50Z","timestamp":1737602450000},"page":"248-253","source":"Crossref","is-referenced-by-count":2,"title":["Clinical outcomes of switching to lonapegsomatropin from somatropin for treatment of pediatric growth hormone deficiency"],"prefix":"10.1515","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1082-2275","authenticated-orcid":false,"given":"Emma","family":"Coyne","sequence":"first","affiliation":[{"name":"Department of Pharmacy , Cincinnati Children\u2019s Hospital Medical Center , Cincinnati , OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7101-2357","authenticated-orcid":false,"given":"Gajanthan","family":"Muthuvel","sequence":"additional","affiliation":[{"name":"Department of Endocrinology , Cincinnati Children\u2019s Hospital Medical Center , Cincinnati , OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0135-4516","authenticated-orcid":false,"given":"Iris","family":"Gutmark-Little","sequence":"additional","affiliation":[{"name":"Department of Endocrinology , Cincinnati Children\u2019s Hospital Medical Center , Cincinnati , OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"2025030110294547834_j_jpem-2024-0496_ref_001","doi-asserted-by":"crossref","unstructured":"Thornton, PS, Maniatis, AK, Aghajanova, E, Chertok, E, Vlachopapadopoulou, E, Lin, Z, et al.. Weekly lonapegsomatropin in treatment-na\u00efve children with growth hormone deficiency: the phase 3 heiGHt trial. J Clin Endocrinol Metab 2021;106:3184\u201395. https:\/\/doi.org\/10.1210\/clinem\/dgab529.","DOI":"10.1210\/clinem\/dgab529"},{"key":"2025030110294547834_j_jpem-2024-0496_ref_002","doi-asserted-by":"crossref","unstructured":"Maniatis, AK, Nadgir, U, Saenger, P, Reifschneider, KL, Abuzzahab, J, Deeb, L, et al.. Switching to weekly lonapegsomatropin from daily somatropin in children with growth hormone deficiency: the fliGHt trial. Horm Res Paediatr 2022;95:233\u201343. https:\/\/doi.org\/10.1159\/000524003.","DOI":"10.1159\/000524003"},{"key":"2025030110294547834_j_jpem-2024-0496_ref_003","doi-asserted-by":"crossref","unstructured":"Lin, Z, Shu, AD, Bach, M, Miller, BS, Rogol, AD. Average IGF-1 prediction for once-weekly lonapegsomatropin in children with growth hormone deficiency. J Endocr Soc 2021;6. https:\/\/doi.org\/10.1210\/jendso\/bvab168.","DOI":"10.1210\/jendso\/bvab168"},{"key":"2025030110294547834_j_jpem-2024-0496_ref_004","doi-asserted-by":"crossref","unstructured":"Bidlingmaier, M, Friedrich, N, Emeny, RT, Spranger, J, Wolthers, OD, Roswall, J, et al.. Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab 2014;99:1712\u201321. https:\/\/doi.org\/10.1210\/jc.2013-3059.","DOI":"10.1210\/jc.2013-3059"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2024-0496\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2024-0496\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T10:31:45Z","timestamp":1740825105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2024-0496\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":4,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,1,17]]},"published-print":{"date-parts":[[2025,3,26]]}},"alternative-id":["10.1515\/jpem-2024-0496"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2024-0496","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]}}}